Wells Fargo says that Abbott Labs (ABT +0.6%) should continue to rally over the near-term,...

Wells Fargo says that Abbott Labs (ABT +0.6%) should continue to rally over the near-term, having already outperformed the S&P since the company announced a deal involving its oral JAK inhibitor for arthritis in late February. Wells expects momentum to continue, anticipating that positive data for the company's oral HCV treatment will provide an additional catalyst in April.